Resistance to targeted therapies in acute myeloid leukemia

Journal article

The introduction of new targeted therapies to the treatment algorithm of acute myeloid leukemia (AML) offers new opportunities, but also presents new challenges. Patients diagnosed with AML receiving targeted therapies as part of lower intensity regimens will relapse inevitably due to primary or secondary resistance mechanisms. In this review, we summarize the current knowledge on the main mechanisms of resistance to targeted therapies in AML. Resistance to FLT3 inhibitors is mainly mediated by on target mutations and dysregulation of downstream pathways. Switching the FLT3 inhibitor has a potential therapeutic benefit. During treatment with IDH inhibitors resistance can develop due to aberrant cell metabolism or secondary site IDH mutations. As a unique resistance mechanism the mutated IDH isotype may switch from IDH1 to IDH2 or vice versa. Resistance to gemtuzumab-ozogamicin is determined by the CD33 isotype and the degradation of the cytotoxin. The main mechanisms of resistance to venetoclax are the dysregulation of alternative pathways especially the upregulation of the BCL-2-analogues MCL-1 and BCL-XL or the induction of an aberrant cell metabolism. The introduction of therapies targeting immune processes will lead to new forms of therapy resistance. Knowing those mechanisms will help to develop strategies that can overcome resistance to treatment.

Authors: Mecklenbrauck, R; Heuser, M

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: Clinical and Experimental Metastasis
• Volume: 40
• Issue: 1
• Pages: 33-44
• Publication date: 2022-11-01
• DOI: 10.1007/s10585-022-10189-0
• EISSN: 1573-7276
• ISSN: 0262-0898
• Language: English
• Keywords: Myeloid; Immunology; Medicine; Biology; Cancer; Myeloid leukemia; Cancer research; Targeted therapy; Venetoclax; Genetics; Gemtuzumab ozogamicin; Internal medicine; CD33; Leukemia